drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00372 | DB00590 | 999 | 1,433 | [
"DDInter1793",
"DDInter592"
] | Thiethylperazine | Doxazosin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Moderate | 1 | [
[
[
999,
24,
1433
]
],
[
[
999,
24,
479
],
[
479,
1,
1433
]
],
[
[
999,
24,
1205
],
[
1205,
40,
1433
]
],
[
[
999,
63,
472
],
[
472,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxazosin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Doxazosin (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Doxazosin (Compou... |
DB00615 | DB06595 | 690 | 1,491 | [
"DDInter1589",
"DDInter1214"
] | Rifabutin | Midostaurin | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
690,
24,
1491
]
],
[
[
690,
24,
1135
],
[
1135,
62,
1491
]
],
[
[
690,
24,
112
],
[
112,
23,
1491
]
],
[
[
690,
24,
761
],
[
761,
... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronid... |
DB06772 | DB10429 | 310 | 200 | [
"DDInter259",
"DDInter282"
] | Cabazitaxel | Candida albicans | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
310,
24,
200
]
],
[
[
310,
63,
1683
],
[
1683,
24,
200
]
],
[
[
310,
25,
976
],
[
976,
24,
200
]
],
[
[
310,
64,
908
],
[
908,
2... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Cabazitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitini... |
DB00346 | DB00468 | 472 | 1,424 | [
"DDInter44",
"DDInter1557"
] | Alfuzosin | Quinine | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
472,
24,
1424
]
],
[
[
472,
6,
8374
],
[
8374,
45,
1424
]
],
[
[
472,
21,
29316
],
[
29316,
60,
1424
]
],
[
[
472,
23,
112
],
[
112,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quinine (Compound)
Alfuzosin (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ... |
DB00197 | DB00425 | 1,324 | 558 | [
"DDInter1881",
"DDInter1970"
] | Troglitazone | Zolpidem | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Moderate | 1 | [
[
[
1324,
24,
558
]
],
[
[
1324,
24,
868
],
[
868,
63,
558
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
558
]
],
[
[
1324,
24,
868
],
[
868,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexa... |
DB01018 | DB01088 | 1,364 | 714 | [
"DDInter847",
"DDInter908"
] | Guanfacine | Iloprost | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1364,
24,
714
]
],
[
[
1364,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1364,
24,
1450
],
[
1450,
63,
714
]
],
[
[
1364,
25,
283
],
[
283,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Emp... |
DB00502 | DB09280 | 1,300 | 1,604 | [
"DDInter853",
"DDInter1101"
] | Haloperidol | Lumacaftor | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
1300,
25,
1604
]
],
[
[
1300,
25,
593
],
[
593,
24,
1604
]
],
[
[
1300,
40,
78
],
[
78,
24,
1604
]
],
[
[
1300,
64,
79
],
[
79,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} m... | Haloperidol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Haloperidol (Compound) resembles Droperidol (Compound) and Droperidol may cause a moderate interaction that could exacerbate dis... |
DB06237 | DB08912 | 438 | 1,040 | [
"DDInter141",
"DDInter462"
] | Avanafil | Dabrafenib | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
438,
24,
1040
]
],
[
[
438,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
438,
21,
28779
],
[
28779,
60,
1040
]
],
[
[
438,
63,
1101
],
[
1101,... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Avanafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Avanafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Avanafil (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Dabrafenib (Compound)
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene... |
DB11718 | DB12161 | 927 | 730 | [
"DDInter640",
"DDInter512"
] | Encorafenib | Deutetrabenazine | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
927,
24,
730
]
],
[
[
927,
62,
112
],
[
112,
23,
730
]
],
[
[
927,
63,
322
],
[
322,
24,
730
]
],
[
[
927,
24,
971
],
[
971,
24,... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Encorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],... | Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin ... |
DB00983 | DB06603 | 480 | 39 | [
"DDInter776",
"DDInter1387"
] | Formoterol | Panobinostat | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
480,
24,
39
]
],
[
[
480,
63,
867
],
[
867,
24,
39
]
],
[
[
480,
24,
688
],
[
688,
24,
39
]
],
[
[
480,
24,
144
],
[
144,
63,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salb... |
DB00818 | DB01041 | 898 | 770 | [
"DDInter1538",
"DDInter1789"
] | Propofol | Thalidomide | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
898,
24,
770
]
],
[
[
898,
6,
6365
],
[
6365,
45,
770
]
],
[
[
898,
21,
29425
],
[
29425,
60,
770
]
],
[
[
898,
24,
609
],
[
609,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
... | Propofol (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound)
Propofol (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Propofol may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB06616 | DB08865 | 594 | 1,593 | [
"DDInter224",
"DDInter448"
] | Bosutinib | Crizotinib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
594,
25,
1593
]
],
[
[
594,
6,
5304
],
[
5304,
45,
1593
]
],
[
[
594,
7,
1881
],
[
1881,
46,
1593
]
],
[
[
594,
18,
4811
],
[
4811,
... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Bosutinib",
"{u} (Compound) binds {v} (Gene)",
"ABL2"
],
[
"ABL2",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
... | Bosutinib (Compound) binds ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)
Bosutinib (Compound) upregulates SREBF2 (Gene) and SREBF2 (Gene) is upregulated by Crizotinib (Compound)
Bosutinib (Compound) downregulates DUSP6 (Gene) and DUSP6 (Gene) is upregulated by Crizotinib (Compound)
Bosutinib (Compound) ... |
DB08868 | DB09036 | 1,011 | 812 | [
"DDInter737",
"DDInter1668"
] | Fingolimod | Siltuximab | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
1011,
25,
812
]
],
[
[
1011,
25,
287
],
[
287,
63,
812
]
],
[
[
1011,
64,
371
],
[
371,
24,
812
]
],
[
[
1011,
24,
496
],
[
496,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarat... | Fingolimod may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Fingolimod may lead to a major life threatening interaction when taken with Propafenone and Propafenone may cau... |
DB01611 | DB04844 | 1,487 | 843 | [
"DDInter893",
"DDInter1778"
] | Hydroxychloroquine | Tetrabenazine | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
1487,
25,
843
]
],
[
[
1487,
63,
479
],
[
479,
40,
843
]
],
[
[
1487,
6,
12523
],
[
12523,
45,
843
]
],
[
[
1487,
21,
29093
],
[
29093... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Hydroxychloroquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Hydroxychloroquine (Compound) causes Fatigue (... |
DB00414 | DB01064 | 590 | 1,148 | [
"DDInter16",
"DDInter987"
] | Acetohexamide | Isoprenaline | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
590,
24,
1148
]
],
[
[
590,
63,
1636
],
[
1636,
24,
1148
]
],
[
[
590,
24,
1523
],
[
1523,
24,
1148
]
],
[
[
590,
23,
1551
],
[
1551,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Labetal... |
DB00252 | DB00835 | 362 | 100 | [
"DDInter1460",
"DDInter245"
] | Phenytoin | Brompheniramine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
362,
24,
100
]
],
[
[
362,
24,
832
],
[
832,
24,
100
]
],
[
[
362,
24,
649
],
[
649,
63,
100
]
],
[
[
362,
6,
8374
],
[
8374,
45... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol... |
DB00332 | DB00376 | 1,089 | 1,105 | [
"DDInter970",
"DDInter1870"
] | Ipratropium | Trihexyphenidyl | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Moderate | 1 | [
[
[
1089,
24,
1105
]
],
[
[
1089,
24,
456
],
[
456,
1,
1105
]
],
[
[
1089,
24,
1386
],
[
1386,
40,
1105
]
],
[
[
1089,
6,
7992
],
[
7992,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
],
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Biperiden and Biperiden (Compound) resembles Trihexyphenidyl (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Procyclidine and Procyclidine (Compound) resembles Trihexyphenid... |
DB00563 | DB01039 | 663 | 535 | [
"DDInter1174",
"DDInter718"
] | Methotrexate | Fenofibrate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
663,
24,
535
]
],
[
[
663,
64,
831
],
[
831,
1,
535
]
],
[
[
663,
21,
28936
],
[
28936,
60,
535
]
],
[
[
663,
63,
522
],
[
522,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Indomethacin"
],
[
"Ind... | Methotrexate may lead to a major life threatening interaction when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound)
Methotrexate (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fenofibrate (Compound)
Methotrexate may cause a moderate interac... |
DB00939 | DB06081 | 1,338 | 1,046 | [
"DDInter1135",
"DDInter286"
] | Meclofenamic acid | Caplacizumab | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
1338,
24,
1046
]
],
[
[
1338,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1338,
63,
1061
],
[
1061,
24,
1046
]
],
[
[
1338,
74,
1512
],
[
15... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenflura... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken ... |
DB06414 | DB15091 | 655 | 676 | [
"DDInter703",
"DDInter1901"
] | Etravirine | Upadacitinib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
655,
24,
676
]
],
[
[
655,
25,
283
],
[
283,
24,
676
]
],
[
[
655,
24,
1593
],
[
1593,
24,
676
]
],
[
[
655,
63,
600
],
[
600,
2... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratin... | Etravirine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may caus... |
DB00867 | DB01067 | 1,052 | 959 | [
"DDInter1606",
"DDInter826"
] | Ritodrine | Glipizide | Adrenergic beta-agonist used to control premature labor. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1052,
24,
959
]
],
[
[
1052,
63,
245
],
[
245,
40,
959
]
],
[
[
1052,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1052,
24,
22
],
[
22,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00515 | DB08871 | 589 | 36 | [
"DDInter387",
"DDInter666"
] | Cisplatin | Eribulin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
589,
24,
36
]
],
[
[
589,
24,
519
],
[
519,
24,
36
]
],
[
[
589,
24,
221
],
[
221,
63,
36
]
],
[
[
589,
63,
1463
],
[
1463,
24,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 ant... |
DB00719 | DB09128 | 1,219 | 1,241 | [
"DDInter149",
"DDInter231"
] | Azatadine | Brexpiprazole | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1219,
24,
1241
]
],
[
[
1219,
24,
407
],
[
407,
63,
1241
]
],
[
[
1219,
24,
543
],
[
543,
24,
1241
]
],
[
[
1219,
63,
506
],
[
506,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may ... |
DB01181 | DB01764 | 1,532 | 805 | [
"DDInter906",
"DDInter469"
] | Ifosfamide | Dalfopristin | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
1532,
24,
805
]
],
[
[
1532,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1532,
63,
473
],
[
473,
24,
805
]
],
[
[
1532,
25,
676
],
[
676,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Ifosfamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Ifosfamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Ifosfamide m... |
DB11113 | DB11853 | 657 | 230 | [
"DDInter307",
"DDInter1577"
] | Castor oil | Relugolix | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of, which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic,... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
657,
24,
230
]
],
[
[
657,
63,
129
],
[
129,
23,
230
]
],
[
[
657,
63,
1213
],
[
1213,
24,
230
]
],
[
[
657,
24,
1297
],
[
1297,
... | [
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasati... |
DB01148 | DB01233 | 1,128 | 1,311 | [
"DDInter738",
"DDInter1197"
] | Flavoxate | Metoclopramide | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1128,
24,
1311
]
],
[
[
1128,
6,
7992
],
[
7992,
45,
1311
]
],
[
[
1128,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1128,
24,
649
],
[
64... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Flavoxate",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",... | Flavoxate (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Metoclopramide (Compound)
Flavoxate (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and... |
DB00762 | DB08827 | 613 | 990 | [
"DDInter973",
"DDInter1085"
] | Irinotecan | Lomitapide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
613,
24,
990
]
],
[
[
613,
25,
1080
],
[
1080,
1,
990
]
],
[
[
613,
6,
8374
],
[
8374,
45,
990
]
],
[
[
613,
21,
28701
],
[
28701,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan... | Irinotecan may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Irinotecan (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect... |
DB01088 | DB06822 | 714 | 802 | [
"DDInter908",
"DDInter1812"
] | Iloprost | Tinzaparin | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
714,
25,
802
]
],
[
[
714,
23,
944
],
[
944,
62,
802
]
],
[
[
714,
24,
222
],
[
222,
24,
802
]
],
[
[
714,
63,
383
],
[
383,
24,... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Iloprost",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Iloprost may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may... |
DB08865 | DB11791 | 1,593 | 785 | [
"DDInter448",
"DDInter287"
] | Crizotinib | Capmatinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1593,
24,
785
]
],
[
[
1593,
25,
1135
],
[
1135,
23,
785
]
],
[
[
1593,
63,
1324
],
[
1324,
24,
785
]
],
[
[
1593,
25,
868
],
[
868,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause ... |
DB00196 | DB00745 | 600 | 307 | [
"DDInter743",
"DDInter1236"
] | Fluconazole | Modafinil | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
600,
23,
307
]
],
[
[
600,
25,
704
],
[
704,
40,
307
]
],
[
[
600,
24,
1236
],
[
1236,
40,
307
]
],
[
[
600,
6,
10215
],
[
10215,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
... | Fluconazole may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Modafinil (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Modafinil (Compound)
Fluconazole (... |
DB08889 | DB13148 | 350 | 1,566 | [
"DDInter299",
"DDInter422"
] | Carfilzomib | Coagulation factor X human | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Coagulation Factor X (Human), is a plasma-derived human blood coagulation factor is used by adults and children (aged 12 years and above) with hereditary Factor X deficiency. However its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe here... | Major | 2 | [
[
[
350,
25,
1566
]
],
[
[
350,
6,
4973
],
[
4973,
45,
1409
],
[
1409,
24,
1566
]
],
[
[
350,
21,
28722
],
[
28722,
60,
1409
],
[
1409,
... | [
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Coagulation factor X human"
]
],
[
[
"Carfilzomib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Coagulation factor X human
Carfilzomib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Apixaban (Compound) ... |
DB00790 | DB01168 | 664 | 1,053 | [
"DDInter1431",
"DDInter1526"
] | Perindopril | Procarbazine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
664,
24,
1053
]
],
[
[
664,
24,
848
],
[
848,
40,
1053
]
],
[
[
664,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
664,
24,
104
],
[
104,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Perindopril (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Perindopril may cause a moderate interacti... |
DB00694 | DB00851 | 51 | 611 | [
"DDInter485",
"DDInter463"
] | Daunorubicin | Dacarbazine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
51,
24,
611
]
],
[
[
51,
5,
11555
],
[
11555,
44,
611
]
],
[
[
51,
6,
7950
],
[
7950,
45,
611
]
],
[
[
51,
7,
10313
],
[
10313,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (D... | Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dacarbazine (Compound)
Daunorubicin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dacarbazine (Compound)
Daunorubicin (Compound) upregulates CADM1 (Gene) and CADM1 (Gene) is upregulated by Dacarbazi... |
DB00687 | DB04868 | 870 | 478 | [
"DDInter747",
"DDInter1293"
] | Fludrocortisone | Nilotinib | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
870,
24,
478
]
],
[
[
870,
6,
1899
],
[
1899,
46,
478
]
],
[
[
870,
21,
28762
],
[
28762,
60,
478
]
],
[
[
870,
23,
307
],
[
307,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) binds {v} (Gene)",
"NR3C1"
],
[
"NR3C1",
"{u} (Gene) is upregulated by {v}... | Fludrocortisone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is upregulated by Nilotinib (Compound)
Fludrocortisone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafi... |
DB00382 | DB01041 | 62 | 770 | [
"DDInter1734",
"DDInter1789"
] | Tacrine | Thalidomide | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
62,
24,
770
]
],
[
[
62,
24,
609
],
[
609,
63,
770
]
],
[
[
62,
63,
521
],
[
521,
24,
770
]
],
[
[
62,
24,
79
],
[
79,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Gose... |
DB00853 | DB01044 | 1,686 | 246 | [
"DDInter1762",
"DDInter809"
] | Temozolomide | Gatifloxacin | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Minor | 0 | [
[
[
1686,
23,
246
]
],
[
[
1686,
23,
739
],
[
739,
1,
246
]
],
[
[
1686,
62,
1176
],
[
1176,
1,
246
]
],
[
[
1686,
23,
945
],
[
945,
... | [
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
... | Temozolomide may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin... |
DB09312 | DB11988 | 967 | 270 | [
"DDInter103",
"DDInter1321"
] | Antilymphocyte immunoglobulin (horse) | Ocrelizumab | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
967,
24,
270
]
],
[
[
967,
23,
1193
],
[
1193,
23,
270
]
],
[
[
967,
63,
713
],
[
713,
24,
270
]
],
[
[
967,
24,
287
],
[
287,
6... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects whe... | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that coul... |
DB00872 | DB08870 | 1,080 | 850 | [
"DDInter438",
"DDInter228"
] | Conivaptan | Brentuximab vedotin | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1080,
24,
850
]
],
[
[
1080,
63,
896
],
[
896,
24,
850
]
],
[
[
1080,
64,
134
],
[
134,
24,
850
]
],
[
[
1080,
25,
1468
],
[
1468,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Conivaptan may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine m... |
DB00364 | DB01059 | 417 | 956 | [
"DDInter1717",
"DDInter1313"
] | Sucralfate | Norfloxacin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
417,
24,
956
]
],
[
[
417,
24,
872
],
[
872,
40,
956
]
],
[
[
417,
63,
1176
],
[
1176,
1,
956
]
],
[
[
417,
24,
1539
],
[
1539,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (... |
DB00574 | DB00939 | 121 | 1,338 | [
"DDInter717",
"DDInter1135"
] | Fenfluramine | Meclofenamic acid | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
121,
24,
1338
]
],
[
[
121,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
121,
24,
1347
],
[
1347,
24,
1338
]
],
[
[
121,
63,
1271
],
[
1271,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Fenfluramine may cause a moderate interaction that could exacerbate diseases when t... |
DB00877 | DB14443 | 629 | 987 | [
"DDInter1678",
"DDInter1931"
] | Sirolimus | Vibrio cholerae CVD 103-HgR strain live antigen | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
629,
24,
987
]
],
[
[
629,
24,
1468
],
[
1468,
24,
987
]
],
[
[
629,
25,
384
],
[
384,
24,
987
]
],
[
[
629,
63,
175
],
[
175,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Sirolimus may lead to a major life threatening interaction when taken with Ide... |
DB00686 | DB01166 | 383 | 477 | [
"DDInter1424",
"DDInter379"
] | Pentosan polysulfate | Cilostazol | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
383,
24,
477
]
],
[
[
383,
21,
28688
],
[
28688,
60,
477
]
],
[
[
383,
63,
126
],
[
126,
23,
477
]
],
[
[
383,
24,
936
],
[
936,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Pentosan polysulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Epistaxis"
],
[
"Epistaxis",
"{u} (... | Pentosan polysulfate (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Cilostazol (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when take... |
DB08895 | DB09118 | 976 | 1,580 | [
"DDInter1825",
"DDInter1711"
] | Tofacitinib | Stiripentol | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
976,
24,
1580
]
],
[
[
976,
24,
283
],
[
283,
63,
1580
]
],
[
[
976,
64,
168
],
[
168,
24,
1580
]
],
[
[
976,
24,
98
],
[
98,
24... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Tofacitinib may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cau... |
DB01006 | DB01166 | 300 | 477 | [
"DDInter1040",
"DDInter379"
] | Letrozole | Cilostazol | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
300,
24,
477
]
],
[
[
300,
6,
8374
],
[
8374,
45,
477
]
],
[
[
300,
21,
28919
],
[
28919,
60,
477
]
],
[
[
300,
23,
801
],
[
801,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Letrozole (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Letrozole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam and Brivara... |
DB01172 | DB01226 | 416 | 1,319 | [
"DDInter1004",
"DDInter1235"
] | Kanamycin | Mivacurium | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Major | 2 | [
[
[
416,
25,
1319
]
],
[
[
416,
64,
648
],
[
648,
1,
1319
]
],
[
[
416,
21,
28680
],
[
28680,
60,
1319
]
],
[
[
416,
64,
1441
],
[
1441,
... | [
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mivacurium"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxacurium"
],
[
"Doxacurium",
"{u} (Co... | Kanamycin may lead to a major life threatening interaction when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Kanamycin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Mivacurium (Compound)
Kanamycin may lead to a major life threatening interaction when taken w... |
DB08870 | DB08875 | 850 | 1,618 | [
"DDInter228",
"DDInter262"
] | Brentuximab vedotin | Cabozantinib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
850,
24,
1618
]
],
[
[
850,
63,
112
],
[
112,
23,
1618
]
],
[
[
850,
24,
384
],
[
384,
63,
1618
]
],
[
[
850,
63,
764
],
[
764,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metroni... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00054 | DB15035 | 1,432 | 503 | [
"DDInter6",
"DDInter1959"
] | Abciximab | Zanubrutinib | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
1432,
25,
503
]
],
[
[
1432,
24,
222
],
[
222,
24,
503
]
],
[
[
1432,
25,
39
],
[
39,
25,
503
]
],
[
[
1432,
24,
885
],
[
885,
2... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Abciximab may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may ... |
DB00460 | DB00563 | 612 | 663 | [
"DDInter1929",
"DDInter1174"
] | Verteporfin | Methotrexate | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
612,
24,
663
]
],
[
[
612,
21,
28681
],
[
28681,
60,
663
]
],
[
[
612,
24,
126
],
[
126,
62,
663
]
],
[
[
612,
24,
1669
],
[
1669,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Si... | Verteporfin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Methotrexate (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken ... |
DB00477 | DB00992 | 216 | 842 | [
"DDInter363",
"DDInter1182"
] | Chlorpromazine | Methyl aminolevulinate (topical) | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
216,
24,
842
]
],
[
[
216,
21,
28643
],
[
28643,
60,
842
]
],
[
[
216,
35,
820
],
[
820,
63,
842
]
],
[
[
216,
40,
1178
],
[
1178,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Chlorpromazine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Methyl aminolevulinate (Compound)
Chlorpromazine (Compound) resembles Alimemazine (Compound) and Chlorpr... |
DB01105 | DB06335 | 222 | 761 | [
"DDInter1665",
"DDInter1646"
] | Sibutramine | Saxagliptin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
222,
24,
761
]
],
[
[
222,
6,
8374
],
[
8374,
45,
761
]
],
[
[
222,
21,
29226
],
[
29226,
60,
761
]
],
[
[
222,
63,
1577
],
[
1577,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Sibutramine (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Saxagliptin (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethia... |
DB00489 | DB01362 | 17 | 497 | [
"DDInter1704",
"DDInter960"
] | Sotalol | Iohexol | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
17,
24,
497
]
],
[
[
17,
24,
258
],
[
258,
40,
497
]
],
[
[
17,
21,
28787
],
[
28787,
60,
497
]
],
[
[
17,
1,
88
],
[
88,
24,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
"Iodix... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Sotalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Sotalol (Compound) resembles Metoprolol (Compound) and M... |
DB00604 | DB01142 | 1,425 | 1,264 | [
"DDInter385",
"DDInter593"
] | Cisapride | Doxepin | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1425,
25,
1264
]
],
[
[
1425,
25,
401
],
[
401,
24,
1264
]
],
[
[
1425,
24,
1335
],
[
1335,
24,
1264
]
],
[
[
1425,
6,
4228
],
[
4228,... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} ma... | Cisapride may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may c... |
DB00835 | DB01174 | 100 | 697 | [
"DDInter245",
"DDInter1442"
] | Brompheniramine | Phenobarbital | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
100,
24,
697
]
],
[
[
100,
63,
759
],
[
759,
1,
697
]
],
[
[
100,
63,
536
],
[
536,
40,
697
]
],
[
[
100,
6,
7603
],
[
7603,
45,... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Phenoba... |
DB00330 | DB08865 | 238 | 1,593 | [
"DDInter689",
"DDInter448"
] | Ethambutol | Crizotinib | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
238,
24,
1593
]
],
[
[
238,
7,
10670
],
[
10670,
46,
1593
]
],
[
[
238,
21,
29047
],
[
29047,
60,
1593
]
],
[
[
238,
24,
148
],
[
148,... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Ethambutol",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL21"
],
[
"KLHL21",
"{u} (Gene) is upregulated by {v} ... | Ethambutol (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Crizotinib (Compound)
Ethambutol (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) is caused by Crizotinib (Compound)
Ethambutol may cause a moderate interaction that could exacerbate ... |
DB00529 | DB01268 | 789 | 1,151 | [
"DDInter779",
"DDInter1731"
] | Foscarnet | Sunitinib | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
789,
24,
1151
]
],
[
[
789,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
789,
23,
112
],
[
112,
23,
1151
]
],
[
[
789,
24,
1148
],
[
1148,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Candida infection"
],
[
"Candida infection",
"{u} (Side Ef... | Foscarnet (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when tak... |
DB00445 | DB00951 | 322 | 1,072 | [
"DDInter655",
"DDInter986"
] | Epirubicin | Isoniazid | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
322,
24,
1072
]
],
[
[
322,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
322,
24,
1130
],
[
1130,
63,
1072
]
],
[
[
322,
63,
912
],
[
912,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Epirubicin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid
... |
DB00209 | DB01591 | 352 | 667 | [
"DDInter1886",
"DDInter1696"
] | Trospium | Solifenacin | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
352,
24,
667
]
],
[
[
352,
6,
7992
],
[
7992,
45,
667
]
],
[
[
352,
54,
19228
],
[
19228,
15,
667
]
],
[
[
352,
21,
28723
],
[
28723,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Trospium",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Trospium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Solifenacin (Compound)
Trospium (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class) and Cholinergic Muscarinic Antagonists (Pharmacologic Class) includes Solifenacin (Compound)
Trospium (Compound) causes Malnutrition (Sid... |
DB00983 | DB08864 | 480 | 786 | [
"DDInter776",
"DDInter1595"
] | Formoterol | Rilpivirine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
480,
24,
786
]
],
[
[
480,
6,
10215
],
[
10215,
45,
786
]
],
[
[
480,
21,
28734
],
[
28734,
60,
786
]
],
[
[
480,
24,
918
],
[
918,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Formoterol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rilpivirine (Compound)
Formoterol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Rilpivirine (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when ... |
DB00041 | DB00619 | 1,648 | 1,419 | [
"DDInter38",
"DDInter909"
] | Aldesleukin | Imatinib | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1648,
24,
1419
]
],
[
[
1648,
24,
1230
],
[
1230,
23,
1419
]
],
[
[
1648,
24,
318
],
[
318,
62,
1419
]
],
[
[
1648,
24,
9
],
[
9,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Imatinib
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escita... |
DB01087 | DB11057 | 1,520 | 720 | [
"DDInter1520",
"DDInter1223"
] | Primaquine | Mineral oil | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1520,
24,
720
]
],
[
[
1520,
24,
927
],
[
927,
63,
720
]
],
[
[
1520,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1520,
25,
1069
],
[
1069,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suni... |
DB09098 | DB11730 | 98 | 351 | [
"DDInter1700",
"DDInter1588"
] | Somatrem | Ribociclib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
98,
24,
351
]
],
[
[
98,
62,
271
],
[
271,
23,
351
]
],
[
[
98,
24,
466
],
[
466,
62,
351
]
],
[
[
98,
63,
222
],
[
222,
23,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Somatrem",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"M... | Somatrem may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide... |
DB00705 | DB01190 | 441 | 568 | [
"DDInter496",
"DDInter398"
] | Delavirdine | Clindamycin | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
441,
24,
568
]
],
[
[
441,
6,
8374
],
[
8374,
45,
568
]
],
[
[
441,
21,
29278
],
[
29278,
60,
568
]
],
[
[
441,
24,
609
],
[
609,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Delavirdine (Compound) causes Inflammation (Side Effect) and Inflammation (Side Effect) is caused by Clindamycin (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Clarithr... |
DB00544 | DB11627 | 970 | 1,367 | [
"DDInter757",
"DDInter860"
] | Fluorouracil | Hepatitis B Vaccine (Recombinant) | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
970,
24,
1367
]
],
[
[
970,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
970,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
970,
24,
259
],
[
259,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Fluorouracil may lead to a major life threatening interaction when taken with Cladrib... |
DB01128 | DB09143 | 918 | 313 | [
"DDInter204",
"DDInter1701"
] | Bicalutamide | Sonidegib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
918,
24,
313
]
],
[
[
918,
63,
1559
],
[
1559,
23,
313
]
],
[
[
918,
25,
478
],
[
478,
24,
313
]
],
[
[
918,
24,
1478
],
[
1478,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Bicalutamide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a... |
DB00364 | DB01193 | 417 | 819 | [
"DDInter1717",
"DDInter12"
] | Sucralfate | Acebutolol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Minor | 0 | [
[
[
417,
23,
819
]
],
[
[
417,
23,
887
],
[
887,
1,
819
]
],
[
[
417,
62,
88
],
[
88,
1,
819
]
],
[
[
417,
21,
28845
],
[
28845,
60,... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pindolol"
],
[
"P... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Sucralfa... |
DB00333 | DB01114 | 576 | 272 | [
"DDInter1166",
"DDInter362"
] | Methadone | Chlorpheniramine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
576,
24,
272
]
],
[
[
576,
1,
358
],
[
358,
63,
272
]
],
[
[
576,
40,
11244
],
[
11244,
1,
272
]
],
[
[
576,
24,
849
],
[
849,
6... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a... | Methadone (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Methadone (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Chlorpheniramine (Compound)
Methadone may cause a moderate i... |
DB01072 | DB12941 | 915 | 466 | [
"DDInter129",
"DDInter481"
] | Atazanavir | Darolutamide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
915,
24,
466
]
],
[
[
915,
23,
1374
],
[
1374,
23,
466
]
],
[
[
915,
25,
351
],
[
351,
23,
466
]
],
[
[
915,
24,
86
],
[
86,
23,... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Atazanavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
... | Atazanavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Atazanavir may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause ... |
DB00005 | DB00022 | 1,057 | 268 | [
"DDInter687",
"DDInter1408"
] | Etanercept | Peginterferon alfa-2b | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
1057,
24,
268
]
],
[
[
1057,
25,
450
],
[
450,
62,
268
]
],
[
[
1057,
25,
1480
],
[
1480,
63,
268
]
],
[
[
1057,
24,
1439
],
[
1439,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
... | Etanercept may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2b
Etanercept may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may caus... |
DB00280 | DB01611 | 494 | 1,487 | [
"DDInter575",
"DDInter893"
] | Disopyramide | Hydroxychloroquine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
494,
25,
1487
]
],
[
[
494,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
494,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
494,
40,
211
],
[
211,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Disopyramide may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Disopyramide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Disopyra... |
DB00655 | DB12332 | 559 | 1,619 | [
"DDInter682",
"DDInter1626"
] | Estrone | Rucaparib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
559,
24,
1619
]
],
[
[
559,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
559,
24,
1213
],
[
1213,
24,
1619
]
],
[
[
559,
40,
1438
],
[
1438,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imat... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may caus... |
DB01142 | DB06702 | 1,264 | 573 | [
"DDInter593",
"DDInter731"
] | Doxepin | Fesoterodine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1264,
24,
573
]
],
[
[
1264,
63,
211
],
[
211,
1,
573
]
],
[
[
1264,
64,
494
],
[
494,
1,
573
]
],
[
[
1264,
6,
12523
],
[
12523,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Doxepin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Doxepin (Co... |
DB00333 | DB06767 | 576 | 732 | [
"DDInter1166",
"DDInter80"
] | Methadone | Ammonium chloride | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions. | Minor | 0 | [
[
[
576,
23,
732
]
],
[
[
576,
25,
1264
],
[
1264,
23,
732
]
],
[
[
576,
40,
1164
],
[
1164,
23,
732
]
],
[
[
576,
1,
939
],
[
939,
... | [
[
[
"Methadone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ammonium chloride"
]
],
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
... | Methadone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Methadone (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a minor interaction that can limit clinical eff... |
DB00912 | DB08869 | 473 | 162 | [
"DDInter1581",
"DDInter1773"
] | Repaglinide | Tesamorelin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and... | Moderate | 1 | [
[
[
473,
24,
162
]
],
[
[
473,
24,
170
],
[
170,
24,
162
]
],
[
[
473,
24,
1344
],
[
1344,
63,
162
]
],
[
[
473,
63,
1645
],
[
1645,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tesamorelin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tesamorelin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin an... |
DB00352 | DB01059 | 482 | 956 | [
"DDInter1814",
"DDInter1313"
] | Tioguanine | Norfloxacin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
482,
23,
956
]
],
[
[
482,
23,
872
],
[
872,
40,
956
]
],
[
[
482,
63,
1176
],
[
1176,
1,
956
]
],
[
[
482,
23,
1539
],
[
1539,
... | [
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
... | Tioguanine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Co... |
DB00480 | DB11627 | 1,668 | 1,367 | [
"DDInter1035",
"DDInter860"
] | Lenalidomide | Hepatitis B Vaccine (Recombinant) | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1668,
24,
1367
]
],
[
[
1668,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
1668,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1668,
24,
259
],
[
259... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Lenalidomide may lead to a major life threatening interaction when taken with Cladr... |
DB00242 | DB11730 | 1,064 | 351 | [
"DDInter392",
"DDInter1588"
] | Cladribine | Ribociclib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1064,
25,
351
]
],
[
[
1064,
24,
466
],
[
466,
62,
351
]
],
[
[
1064,
25,
310
],
[
310,
24,
351
]
],
[
[
1064,
24,
987
],
[
987,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may ca... |
DB01224 | DB01234 | 623 | 1,220 | [
"DDInter1553",
"DDInter513"
] | Quetiapine | Dexamethasone | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
623,
24,
1220
]
],
[
[
623,
6,
21998
],
[
21998,
45,
1220
]
],
[
[
623,
7,
2384
],
[
2384,
46,
1220
]
],
[
[
623,
18,
2186
],
[
2186,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is boun... | Quetiapine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Quetiapine (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Dexamethasone (Compound)
Quetiapine (Compound) downregulates HSPA1A (Gene) and HSPA1A (Gene) is downregulated by Dexamethason... |
DB00995 | DB11989 | 1,112 | 1,434 | [
"DDInter139",
"DDInter183"
] | Auranofin | Benznidazole | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1112,
24,
1434
]
],
[
[
1112,
24,
375
],
[
375,
24,
1434
]
],
[
[
1112,
24,
148
],
[
148,
63,
1434
]
],
[
[
1112,
63,
581
],
[
581,
... | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
... | Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Secni... |
DB01403 | DB05812 | 9 | 1,374 | [
"DDInter1175",
"DDInter8"
] | Methotrimeprazine | Abiraterone | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
9,
24,
1374
]
],
[
[
9,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
9,
21,
30550
],
[
30550,
60,
1374
]
],
[
[
9,
62,
112
],
[
112,
2... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {... | Methotrimeprazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Methotrimeprazine (Compound) causes Sudden death (Side Effect) and Sudden death (Side Effect) is caused by Abiraterone (Compound)
Methotrimeprazine may cause a minor interaction that can limit clinical effects when tak... |
DB00108 | DB14444 | 1,066 | 151 | [
"DDInter1268",
"DDInter924"
] | Natalizumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1066,
24,
151
]
],
[
[
1066,
64,
66
],
[
66,
24,
151
]
],
[
[
1066,
25,
134
],
[
134,
24,
151
]
],
[
[
1066,
25,
994
],
[
994,
6... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening intera... | Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Natalizumab may lead to a major life threatening in... |
DB01096 | DB06702 | 678 | 573 | [
"DDInter1356",
"DDInter731"
] | Oxamniquine | Fesoterodine | An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Ex... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
678,
24,
573
]
],
[
[
678,
62,
211
],
[
211,
1,
573
]
],
[
[
678,
6,
12523
],
[
12523,
45,
573
]
],
[
[
678,
63,
1387
],
[
1387,
... | [
[
[
"Oxamniquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Oxamniquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolterodine"
],
[... | Oxamniquine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Oxamniquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Oxamniquine may cause a moderate interaction that could exac... |
DB00903 | DB01249 | 1,680 | 258 | [
"DDInter686",
"DDInter958"
] | Etacrynic acid | Iodixanol | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
1680,
24,
258
]
],
[
[
1680,
24,
497
],
[
497,
1,
258
]
],
[
[
1680,
18,
7460
],
[
7460,
57,
258
]
],
[
[
1680,
21,
28748
],
[
28748,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Etacrynic acid (Compound) downregulates AKR7A2 (Gene) and AKR7A2 (Gene) is downregulated by Iodixanol (Compound)
Etacrynic acid (Compound) causes Vertigo (Side Eff... |
DB00851 | DB01177 | 611 | 77 | [
"DDInter463",
"DDInter904"
] | Dacarbazine | Idarubicin | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
611,
24,
77
]
],
[
[
611,
5,
11555
],
[
11555,
44,
77
]
],
[
[
611,
7,
10313
],
[
10313,
46,
77
]
],
[
[
611,
18,
9650
],
[
9650,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Dacarbazine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Dacarbazine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Dacarbazine (Compound) upregulates CADM1 (Gene) and CADM1 (Gene) is upregulated by Idarubicin (Compound)
Dacarbazine (Compound) downregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated b... |
DB00701 | DB08901 | 1,091 | 1,468 | [
"DDInter90",
"DDInter1492"
] | Amprenavir | Ponatinib | Amprenavir is a protease inhibitor used to treat HIV infection. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1091,
25,
1468
]
],
[
[
1091,
25,
478
],
[
478,
24,
1468
]
],
[
[
1091,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
1091,
21,
28883
],
[
28... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Amprenavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Amprenavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Amprenavir (Compound) causes Skin dis... |
DB01155 | DB01259 | 872 | 392 | [
"DDInter813",
"DDInter1024"
] | Gemifloxacin | Lapatinib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
872,
24,
392
]
],
[
[
872,
21,
29429
],
[
29429,
60,
392
]
],
[
[
872,
62,
112
],
[
112,
23,
392
]
],
[
[
872,
63,
918
],
[
918,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side ... | Gemifloxacin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when t... |
DB01115 | DB11348 | 336 | 1,065 | [
"DDInter1291",
"DDInter279"
] | Nifedipine | Calcium Phosphate | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
336,
24,
1065
]
],
[
[
336,
1,
1081
],
[
1081,
24,
1065
]
],
[
[
336,
40,
854
],
[
854,
24,
1065
]
],
[
[
336,
1,
1081
],
[
1081,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause ... | Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nifedipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB00863 | DB09104 | 1,194 | 286 | [
"DDInter1568",
"DDInter1118"
] | Ranitidine | Magnesium hydroxide | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
1194,
23,
286
]
],
[
[
1194,
62,
109
],
[
109,
23,
286
]
],
[
[
1194,
63,
1382
],
[
1382,
23,
286
]
],
[
[
1194,
40,
1127
],
[
1127,
... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Duloxetine"
],
... | Ranitidine may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Mi... |
DB00258 | DB01136 | 666 | 772 | [
"DDInter270",
"DDInter305"
] | Calcium acetate | Carvedilol | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
666,
24,
772
]
],
[
[
666,
21,
28789
],
[
28789,
60,
772
]
],
[
[
666,
24,
542
],
[
542,
23,
772
]
],
[
[
666,
21,
28789
],
[
28789,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness"... | Calcium acetate (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Carvedilol (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit cl... |
DB00262 | DB05273 | 552 | 507 | [
"DDInter302",
"DDInter1638"
] | Carmustine | Samarium (153Sm) lexidronam | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
552,
25,
507
]
],
[
[
552,
24,
248
],
[
248,
24,
507
]
],
[
[
552,
24,
270
],
[
270,
63,
507
]
],
[
[
552,
24,
970
],
[
970,
25,... | [
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Carmustine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00959 | DB08938 | 1,486 | 1,384 | [
"DDInter1191",
"DDInter1112"
] | Methylprednisolone | Magaldrate | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1486,
23,
1384
]
],
[
[
1486,
40,
167
],
[
167,
23,
1384
]
],
[
[
1486,
24,
699
],
[
699,
23,
1384
]
],
[
[
1486,
63,
461
],
[
461,
... | [
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{... | Methylprednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interacti... |
DB00374 | DB01241 | 1,061 | 1,206 | [
"DDInter1852",
"DDInter812"
] | Treprostinil | Gemfibrozil | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA appr... | Moderate | 1 | [
[
[
1061,
24,
1206
]
],
[
[
1061,
6,
6017
],
[
6017,
45,
1206
]
],
[
[
1061,
18,
16662
],
[
16662,
46,
1206
]
],
[
[
1061,
18,
9205
],
[
9... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Treprostinil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compou... | Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Gemfibrozil (Compound)
Treprostinil (Compound) downregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Gemfibrozil (Compound)
Treprostinil (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Gemfibrozil (Compound)
Tre... |
DB00465 | DB11793 | 886 | 738 | [
"DDInter1010",
"DDInter1297"
] | Ketorolac | Niraparib | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
886,
24,
738
]
],
[
[
886,
25,
1213
],
[
1213,
24,
738
]
],
[
[
886,
63,
1578
],
[
1578,
24,
738
]
],
[
[
886,
24,
372
],
[
372,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Ketorolac may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moder... |
DB01182 | DB05294 | 371 | 1,069 | [
"DDInter1534",
"DDInter1917"
] | Propafenone | Vandetanib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
371,
25,
1069
]
],
[
[
371,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
371,
21,
29343
],
[
29343,
60,
1069
]
],
[
[
371,
62,
112
],
[
112,
... | [
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Propafenone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vande... | Propafenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Propafenone (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Propafenone may cause a minor interaction that can limit clinical effects ... |
DB00011 | DB05273 | 1,451 | 507 | [
"DDInter944",
"DDInter1638"
] | Interferon alfa-n1 | Samarium (153Sm) lexidronam | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
1451,
25,
507
]
],
[
[
1451,
24,
248
],
[
248,
24,
507
]
],
[
[
1451,
24,
270
],
[
270,
63,
507
]
],
[
[
1451,
25,
1101
],
[
1101,
... | [
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valgancic... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Interferon alfa-n1 may cause a moderate interaction that could exacerbate disea... |
DB00959 | DB01010 | 1,486 | 61 | [
"DDInter1191",
"DDInter622"
] | Methylprednisolone | Edrophonium | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
1486,
24,
61
]
],
[
[
1486,
24,
1372
],
[
1372,
63,
61
]
],
[
[
1486,
21,
28658
],
[
28658,
60,
61
]
],
[
[
1486,
25,
1011
],
[
1011,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmin... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium
Methylprednisolone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by E... |
DB00834 | DB11581 | 932 | 1,456 | [
"DDInter1215",
"DDInter1926"
] | Mifepristone | Venetoclax | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
932,
25,
1456
]
],
[
[
932,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
932,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
932,
24,
86
],
[
86,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Mifepristone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Mifepristone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate inte... |
DB01088 | DB09038 | 714 | 1,450 | [
"DDInter908",
"DDInter636"
] | Iloprost | Empagliflozin | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
714,
24,
1450
]
],
[
[
714,
63,
461
],
[
461,
24,
1450
]
],
[
[
714,
24,
911
],
[
911,
24,
1450
]
],
[
[
714,
24,
1455
],
[
1455,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azi... |
DB00295 | DB01173 | 475 | 358 | [
"DDInter1244",
"DDInter1349"
] | Morphine | Orphenadrine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Major | 2 | [
[
[
475,
25,
358
]
],
[
[
475,
24,
211
],
[
211,
1,
358
]
],
[
[
475,
24,
272
],
[
272,
24,
358
]
],
[
[
475,
24,
820
],
[
820,
63,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orphenadrine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interactio... |
DB01069 | DB01230 | 401 | 795 | [
"DDInter1533",
"DDInter1416"
] | Promethazine | Pemoline | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Moderate | 1 | [
[
[
401,
24,
795
]
],
[
[
401,
24,
1662
],
[
1662,
63,
795
]
],
[
[
401,
63,
1503
],
[
1503,
24,
795
]
],
[
[
401,
25,
593
],
[
593,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Linda... |
DB09291 | DB12010 | 741 | 214 | [
"DDInter1615",
"DDInter785"
] | Rolapitant | Fostamatinib | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
741,
24,
214
]
],
[
[
741,
64,
690
],
[
690,
24,
214
]
],
[
[
741,
24,
861
],
[
861,
63,
214
]
],
[
[
741,
63,
866
],
[
866,
24,... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Rolapitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabutin... | Rolapitant may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.